References
- Saven A, Kawasaki H, Carrera C, Waltz T, Copelana B, Zyroff J, Kost M, Carson D, Beutter E, Piro L. 2Chlorodeoxyadenosine dose escalation in non hematologic malignancies. J. of Clin. Oncol. 1993; 11: 671–678
- Cheson B D, Vena D A, Foss F M, Sorensen J M. Neurotoxicity of purine analogs: a review. J. of Clin. Oncol. 1994; 11: 2216–2228
- Liliemark J, Petterson B, Juliusson G. The relationship between plasma 2-Chloro-2′deoxyadenosine (CdA) and cellular CdA nucleotides(C'dAN) after intermittent and continuous i.v. infusion in patients with chronic lymphocytic leukemia. Blood 1991; 78(Suppl)33 a
- Djaldetti R, Hart J, Alexandrova S, Cohen S, Beilin B, Djaldetti M, Bessler H. Effect of high doses of 2-CdA on Schwann cells of mouse peripheral nerve. J. Submicrose. Cytol. Pathol. Jul, 1996; 28(3)319–23
- Gregson N A, Koblar S, Hughes R AC. Antibodies to gangliosides in Guillain-Barré syndrome: specifity and relationship to Clinical features. Quarterly Journal of Medicine. 1993; 86: 111–117
- Nagai Y, Momoi T, Saito M, Mitsuzawa E, Ohtami S. Ganglioside syndrome. a new autoimmune neurologic disorder. experimentally induced with brain gangliosides. Neurosci Lett 1976; 2: 107–11